

> General (NEJM 2017;376:2168)


# MYELOPROLIFERATIVE NEOPLASMS (MPN)

General (_NEJM_ 2017;376:2168)

• Results from clonal expansion of multipotent hematopoietic stem cell

• Different from MDS in that the cells are not dysplastic (ie, normally developed)

• Categories of MPN: polycythemia vera (PV); essential thrombocythemia (ET); primary myelofibrosis (PMF); chronic myelogenous leukemia (CML), BCR-ABL1 ⊕; atypical CML (aCML); chronic neutrophilic leukemia (CNL); systemic mastocytosis; chronic eosinophilic leukemia, not otherwise specified; myeloproliferative neoplasms unclassifiable

• Mutations useful as clonal markers & dx tools:

Gain of fxn mutations in **_JAK2_** V617F (Janus kinase) frequently present (PV ~95%, ET ~50%, PMF ~50%; _NEJM_ 2005;352:1779)

### _BCR-ABL_ fusion in **all** cases of CML; **_SETBP1_** in aCML

### _CALR_ exon 9 mutation (most MPNs without _JAK2_ or _MPL_ mutation, including ~25% of ET, ~35% of myelofibrosis 病人; _NEJM_ 2013;369:2379 & 2391)

### _MPL_, **_TET2, & ASXL1_** mutation with lower frequency

### _CSF3R_ mutation present in ~60% of CNL; **_KIT_** in 90% of systemic mastocytosis

POLYCYTHEMIA VERA (PV)

定義

• ↑ in RBC mass ± ↑ granulocytes and platelets in the absence of physiologic stimulus

原因 of erythrocytosis

• Relative ↑ RBC (↓ plasma): dehydration; “stress” erythrocytosis (Gaisböck’s syndrome)

• _Absolute_ ↑ RBC: 1° (PV, other MPD) or 2° due to **hypoxia; carboxyhemoglobinemia; inappropriate erythropoietin** (renal, hepatic, cerebellar tumors); Cushing’s syndrome

臨床表現 (common between PV and ET)

• Symptoms → often termed “vasomotor symptoms”

### Hyperviscosity (erythrocytosis): headache, dizziness, tinnitus, blurred vision

### Thrombosis (hyperviscosity, thrombocytosis): transient visual disturbances (amaurosis, ocular migraine); Budd-Chiari syndrome; erythromelalgia = intense burning, pain and erythema of extremities due to microvascular ischemia; ↑ risk of **DVT**, **MI**, **stroke.** Risk of thrombosis highly correlated with ↑ WBC in PV and ET (see below).

### Bleeding (abnormal platelet function): easy bruising, epistaxis, GI bleeding

↑ histamine from basophils → **pruritus**, peptic ulcers; ↑ uric acid (cell turnover) → gout

• Signs: **plethora**, **splenomegaly**, hypertension, engorged retinal veins

• Expression profiling beyond _JAK2_ may define different phenotypes (_NEJM_ 2014;371:808)

Diagnostic evaluation

• Men: Hb >16.5 g/dL or HCT >49%, women: Hb >16 g/dL or HCT >48%, or ↑ red cell mass

• BM bx → hypercellularity for age, trilineage growth, pleomorphic mature megakaryocytes

• **_JAK2_ V617F** mutation in ~95% of PV; other 病人 typically harbor _JAK2_ exon 12 mutations

• ✔ Epo to rule out secondary causes of erythrocytosis; **if Epo** ↓, **PV more likely**

If Epo ↑, then ✔ SaO2 or PaO2, carboxyhemoglobin, BM exam

• ± ↑ WBC, platelets, basophils; ↑ uric acid, leukocyte alkaline phosphatase, vit B12

• Peripheral smear → no morphologic abnormalities

治療

• **Phlebotomy** to goal Hct <45% (_NEJM_ 2013;368:22), consider <42% in women

• **Low-dose ASA** in all 病人 (_NEJM_ 2004;350:114)

• **Hydroxyurea** if high risk of thrombosis (age ≥60, prior thrombosis) or symptomatic thrombocytosis (plt >1.5 × 106/µL), or if inadequate Hct by phlebotomy alone

• PEG IFNα preferred in younger 病人 and pregnancy (_Lancet Haematol_ 2017;4:e165)

• Ruxolitinib (JAK1/2 inhibitor) if refractory to or intolerant of hydroxyurea (_NEJM_ 2015;372:426)

• Supportive: allopurinol (gout), H2\-blockers/antihistamines (pruritus)

Prognosis

• Median survival with Rx ~13.5 y (_Blood_ 2014;124:2507); ↑ age, WBC, additional acquired somatic mutations → worse prognosis (_Haematol_ 2013;160:251)

• Post-PV myelofibrosis (spent phase) occurs in 10–20% of cases, usually after 10 y

• Risk of transformation into acute leukemia (<2–5%)

ESSENTIAL THROMBOCYTHEMIA (ET)

定義

• Sustained ↑ in platelets (>450,000/µL) ± ↑ RBC and granulocytes

原因 of thrombocytosis

• 1° = ET or other MPN; myelodysplastic syndromes (5q-syndrome); RARS-T

• 2° = **reactive thrombocytosis:** inflammation (RA, IBD, vasculitis), infection, acute

bleeding, iron deficiency, postsplenectomy, neoplasms (eg, Hodgkin lymphoma)

• Of patients with plt >106/µL, <1 in 6 will have ET

臨床表現 (also see “Polycythemia Vera”)

• Thrombosis with erythromelalgia (risk of thrombosis highest in 病人 with leukocytosis), bleeding, pruritus; mild splenomegaly; migraine, TIA; early fetal loss

Diagnostic evaluation

• Peripheral smear: large hypogranular platelets

• BM bx: megakaryocytic hyperplasia; absence of Philadelphia chromosome; rarely minor reticulin fibrosis; normal iron stores; if atypical megakaryoctyes, consider pre-PMF

• Mutations: **_JAK2_ V617F** in 60-65%; **_CALR_** in 20-25%; **_MPL_** in 5%; triple negative 10-15%

• Patients should not meet WHO criteria for diagnosis of CML, PV, PMF, or MDS

![](https://i.imgur.com/oHAAzJN.jpg)

Prognosis

• Low-risk 病人 have overall survival ≈ control population

• Risk of transformation into acute leukemia <2%; risk of progression to MF similar

PRIMARY MYELOFIBROSIS (PMF)

定義

• Clonal myeloproliferation with reactive marrow fibrosis & extramedullary hematopoiesis

• Prefibrotic stage (pre-PMF): megakaryocyte prolif, grade 1 reticulin fibrosis, ↑ BM cellularity. Important to distinguish from ET: ↑ thrombosis, ↑ progression, ↓ survival (_Blood_ 2012;120:569)

原因 of myelofibrosis

• Myeloproliferative neoplasm = primary myelofibrosis; post-PV/ET myelofibrosis

• Other hematologic (CML, AML, ALL, MDS) and solid cancers (breast, prostate)

• Autoimmune (SLE and other collagen vascular disorders)

• Toxins (benzene); radiation; granulomas (TB, fungal, sarcoid); deposition dis. (Gaucher’s)

臨床表現 (_BJH_ 2012;158:453)

• Ineffective erythropoiesis → anemia; extramedullary hematopoiesis → **massive splenomegaly** (abdominal pain, early satiety) ± hepatomegaly

• Tumor bulk and ↑ cell turnover → fatigue, weight loss, fever, sweats

Diagnostic evaluation (_JAMA_ 2010;303:2513; _Blood_ 2016;127:2391)

• Anemia with variable WBC and platelet counts

• Peripheral smear → “**leukoerythroblastic**” (**teardrop cells**, nucleated RBCs, immature WBCs); large abnormal platelets

• BM aspirate → “dry” tap; BM bx → **severe fibrosis**, replacement by reticulin & collagen

• **_JAK2_ V617F** in 45–50%; **_CALR_** mut in 45–50%, **_MPL_** mut in 7–10%, triple neg in 1–2%

• No BCR-ABL translocation; also does not meet criteria for PV or MDS

治療 (_Blood_ 2011;117:3494)

• In absence of adverse prognostic factors (eg, anemia or sx) → no 治療

• Allogeneic HSCT only potential cure → consider in young 病人 with poor prognosis

• Supportive care: **transfusions;** ESA if Epo <500 but risk worsening splenomegaly; consider androgens vs immunomodulatory agents (eg, lenalidomide) + prednisone; ? splenectomy if refractory to transfusions, failed chemoRx, painful splenomegaly

• Hydroxyurea for significant leukocytosis or thrombocytosis

• Ruxolitinib (JAK1/JAK2 inhibitor) ↓ sx, ↓ splenomegaly, ↑ survival (_NEJM_ 2012;366:787 & 799)

• JAK2 inh: pacritinib, momelotinib, & fedratinib are in phase 3 trials (_JAMA Oncology_ 2018;4:652)

• Median survival ~6 y (_JCO_ 2012;30:2981); transformation into AML occurs at a rate of ~8%/y
